Key facts
- Accession Therapeutics’s last known valuation is $82.8M (Sep 2024).
- It has raised $107.9M; the latest was Later Stage VC ($40.1M) in Dec 2025.
- Notable investors include Primavera Venture Partners, iGlobe Partners, BioIndustry Association, Birk Venture, Ro Invest — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Accession Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Accession Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Accession Therapeutics
Developer of an immuno-oncology therapeutics platform designed to make oncology therapeutics targeted and potent. The company specializes in immunotherapy that is specific, broad in action to kill all cancer cell variants present and potent in activating the full immune system arsenal local to the tumor, enabling doctors to treat the widespread forms of cancer.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2020
- Employees
- 45
- Website
- accessiontherapeutics.com/
- Ownership
- Privately Held (backing)
Accession Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accession Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accession Therapeutics in its N-PORT filings yet. We sweep new filings monthly.